EIF2AK3 and neoplasm: Based on the positive correlation of pERK levels and sorafenib effectiveness in cancer cell lines, mouse models, patient-derived xenograft models, and by patient tumor imaging, we conclude that pERK is a strong prognostic biomarker candidate to predict sorafenib treatment effectiveness.